Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108

AIDS
Judith A AbergACTG A5108 team

Abstract

Nelfinavir, an HIV protease inhibitor with numerous drug-drug interactions, is associated with dyslipidemia. Pravastatin is the preferred statin prescribed for HIV-associated dyslipidemia. To examine the effect of nelfinavir on pravastatin pharmacokinetics. Open-label study in healthy HIV-seronegative adults conducted at the AIDS Clinical Trials Group sites in the United States. Subjects received pravastatin 40 mg daily and underwent intensive sampling for pharmacokinetics on day 3. Subjects took only nelfinavir 1250 mg twice daily on days 4-12. On days 13-15, subjects continued nelfinavir and reinitiated pravastatin. Plasma samples were collected over 24 h for the calculation of pravastatin area under the concentration-time curve for 0-24 h on days 3 and 16. Data from 14 subjects with complete pharmacokinetic samples were available for analysis. The median within-subject percentage change in pravastatin AUC was a decrease of 46.5%. Pravastatin maximum plasma concentrations were also lower when pravastatin was administered with nelfinavir. Median values for the maximum plasma concentrations were 27.9 and 12.4 ng/ml for days 3 and 16, respectively, and the median within-subject decrease was 40.1%. Coadministration of pravastatin...Continue Reading

References

Feb 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·K C Yeh, K C Kwan
Apr 25, 2000·Drugs·A Bardsley-Elliot, G L Plosker
Jun 18, 2003·Clinical Pharmacology and Therapeutics·Carl KyrklundPertti J Neuvonen
Jun 18, 2003·Clinical Pharmacology and Therapeutics·Yohei NishizatoYuichi Sugiyama
Aug 28, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael P DubéUNKNOWN HIV Medical Association of the Infectious Disease Society of America
Jan 30, 2004·British Journal of Clinical Pharmacology·Carl KyrklundPertti J Neuvonen
Mar 24, 2004·British Journal of Plastic Surgery·R H ShahP M Arnstein
Jun 17, 2004·American Heart Journal·Shelina M JamalStavroula Christopoulos
Aug 4, 2004·Clinical Pharmacology and Therapeutics·Steven G SimonsonDennis W Schneck
Jun 21, 2005·Current Infectious Disease Reports·Michelle S Cespedes, Judith A Aberg
Jun 28, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·John G GerberUNKNOWN AIDS Clinical Trials Group A5108 Team
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Jae-Yong ChungIn-Jin Jang

❮ Previous
Next ❯

Citations

Jul 31, 2009·European Journal of Clinical Pharmacology·Hanna Marita SeidlingWalter Emil Haefeli
May 25, 2013·Clinical Pharmacokinetics·Benoit ChauvinAnne-Marie Taburet
Nov 17, 2010·Nature Reviews. Endocrinology·Christina G FiorenzaChristos S Mantzoros
May 16, 2008·AIDS Patient Care and STDs·Graeme MoyleChristos Tsoukas
Jun 18, 2010·The Nurse Practitioner·Kristine A Scordo
Dec 19, 2008·Cardiology in Review·Gretchen M Ray
Jun 4, 2008·Journal of Cardiovascular Pharmacology·Anthony J BustiReza Mehvar
Sep 11, 2007·Diabetes, Obesity & Metabolism·R A Bradbury, K Samaras
Aug 19, 2007·Expert Opinion on Drug Metabolism & Toxicology·Andrew Walubo
Jan 5, 2012·Clinical Lipidology·Carlos D Malvestutto, Judith A Aberg
Dec 30, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sudershan SinghHeidi M Crane
Sep 10, 2014·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Carlos D MalvestuttoJudith A Aberg
Apr 17, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Matthijs van LuinDavid M Burger
Apr 18, 2009·Current Opinion in HIV and AIDS·David BurgerPeter Reiss
Feb 17, 2009·Endocrinology and Metabolism Clinics of North America·Judith A Aberg
Dec 17, 2011·Journal of Clinical Pharmacology·Christina L AquilanteMaha S Sidhom
Jun 19, 2008·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Nasser E Mikhail
Apr 17, 2007·HIV Clinical Trials·Scott R EvansUNKNOWN A5087 Study Team
Dec 7, 2007·Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria·P AmarilesM J Faus

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.